Non-small cell lung cancer, ROS1-positive
Revision as of 16:27, 22 March 2018 by Warner-admin (talk | contribs) (Text replacement - "?Variant |limit=10000|format=sum}} variants" to "?Variant |limit=10000|format=sum}} variants")
Section editor | |
---|---|
Travis Osterman, DO, MS Nashville, TN Twitter: TravisOsterman |
Note: these are biomarker-specific regimens, please see the main NSCLC page for other regimens.
6 regimens on this page
8 variants on this page
|
Advanced or metastatic disease, ROS1 inhibitor-naive
Crizotinib monotherapy
back to top |
Regimen
Study | Evidence | Efficacy |
---|---|---|
Shaw et al. 2014 | Phase I, >20 pts | ORR: 72% (95% CI, 58-84) |
Chemotherapy
- Crizotinib (Xalkori) 250 mg PO BID
28-day cycles
References
- Shaw AT, Ou SH, Bang YJ, Camidge DR, Solomon BJ, Salgia R, Riely GJ, Varella-Garcia M, Shapiro GI, Costa DB, Doebele RC, Le LP, Zheng Z, Tan W, Stephenson P, Shreeve SM, Tye LM, Christensen JG, Wilner KD, Clark JW, Iafrate AJ. Crizotinib in ROS1-rearranged non-small-cell lung cancer. N Engl J Med. 2014 Nov 20;371(21):1963-71. Epub 2014 Sep 27. link to original article link to PMC article contains verified protocol PubMed